InsiderSource
AKBA

Akebia Therapeutics, Inc.

SEC CIK 1517022
$0.8990 −36.2% · 90 days
90-day buys
$0
0 open-market
90-day sells
$0
0 open-market
Net insider flow
+$0
Net buying
Filings shown
35
Most recent
Advertisement

At a glance

Insiders at AKBA have made no open-market trades in the last 90 days — the activity below is grants, option exercises, and other routine filings.

Largest recent trade: Butler John P. sold $159.7K of AKBA, trimming their stake 3%.

Most active filer: Butler John P., with 8 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for AKBA, newest first
View on SEC EDGAR ↗
AKBA
Akebia Therapeutics, Inc.
Buy Butler John P. · Director, CEO and President · Open-market purchase · filed Mar 5, 2026 ΔOwn +2.1%

Butler John P., AKBA's CEO, spent $86.6K of their own money on 69,270 shares at $1, growing their stake 2%.

+$86.6K
69,270 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Malabre Richard C · SVP, Chief Accounting Officer · Open-market sale · filed Feb 4, 2026 ΔOwn −10%

Malabre Richard C sold $50.2K of AKBA, trimming their stake 10%.

−$50.2K
36,142 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Malabre Richard C · SVP, Chief Accounting Officer · Open-market sale · filed Feb 4, 2026 ΔOwn −4.3%

Malabre Richard C sold $18.6K of AKBA, trimming their stake 4%.

−$18.6K
13,382 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Grund Nicholas · Chief Commercial Officer · Open-market sale · filed Feb 4, 2026 ΔOwn −8.3%

Grund Nicholas sold $74.5K of AKBA, trimming their stake 8%.

−$74.5K
53,585 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Grund Nicholas · Chief Commercial Officer · Open-market sale · filed Feb 4, 2026 ΔOwn −5.3%

Grund Nicholas sold $43.4K of AKBA, trimming their stake 5%.

−$43.4K
31,244 sh @ $1
Advertisement
AKBA
Akebia Therapeutics, Inc.
Sell Burke Steven Keith · SVP, Chief Medical Officer · Open-market sale · filed Feb 4, 2026 ΔOwn −2.1%

Burke Steven Keith sold $30K of AKBA, trimming their stake 2%.

−$30K
21,582 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Burke Steven Keith · SVP, Chief Medical Officer · Open-market sale · filed Feb 4, 2026 ΔOwn −2.6%

Burke Steven Keith sold $35.3K of AKBA, trimming their stake 3%.

−$35.3K
25,375 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Burke Steven Keith · SVP, Chief Medical Officer · Open-market sale · filed Feb 4, 2026 ΔOwn −2.1%

Burke Steven Keith sold $28.8K of AKBA, trimming their stake 2%.

−$28.8K
20,701 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Rucci Carolyn M. · SVP, Chief Legal Officer · Open-market sale · filed Feb 4, 2026 ΔOwn −2.6%

Rucci Carolyn M. sold $23.4K of AKBA, trimming their stake 3%.

−$23.4K
16,846 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Rucci Carolyn M. · SVP, Chief Legal Officer · Open-market sale · filed Feb 4, 2026 ΔOwn −4.0%

Rucci Carolyn M. sold $35.3K of AKBA, trimming their stake 4%.

−$35.3K
25,382 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Rucci Carolyn M. · SVP, Chief Legal Officer · Open-market sale · filed Feb 4, 2026 ΔOwn −4.5%

Rucci Carolyn M. sold $38.3K of AKBA, trimming their stake 4%.

−$38.3K
27,544 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Ostrowski Erik · SVP, CFO, CBO & Treasurer · Open-market sale · filed Feb 4, 2026 ΔOwn −4.9%

Ostrowski Erik sold $48.6K of AKBA, trimming their stake 5%.

−$48.6K
34,951 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Butler John P. · Director, CEO and President · Open-market sale · filed Feb 4, 2026 ΔOwn −1.3%

Butler John P. sold $64.9K of AKBA, trimming their stake 1%.

−$64.9K
46,660 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Butler John P. · Director, CEO and President · Open-market sale · filed Feb 4, 2026 ΔOwn −2.8%

Butler John P. sold $133.5K of AKBA, trimming their stake 3%.

−$133.5K
96,065 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Butler John P. · Director, CEO and President · Open-market sale · filed Feb 4, 2026 ΔOwn −3.5%

Butler John P. sold $159.7K of AKBA, trimming their stake 3%.

−$159.7K
114,891 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Butler John P. · Director, CEO and President · Open-market sale · filed Feb 4, 2026 ΔOwn −2.5%

Butler John P. sold $116.3K of AKBA, trimming their stake 2%.

−$116.3K
83,689 sh @ $1
AKBA
Akebia Therapeutics, Inc.
Sell Ostrowski Erik · SVP, CFO, CBO & Treasurer · Open-market sale · filed Jul 1, 2025 ΔOwn −7.6%

Ostrowski Erik sold $151.6K of AKBA, trimming their stake 8%.

−$151.6K
41,314 sh @ $4
Advertisement

About AKBA insider activity

This page tracks every recent Form 4 filed for Akebia Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is AKBA insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Akebia Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.